Alexei Shir¹, Manfred Ogris², Ernst Wagner², Alexander Levitzki¹*

1 Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel,

2 Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitat, Munich, Germany

* To whom correspondence should be addressed. E-mail: LEVITZKI@vms. huji.ac.il

Background

Glioblastoma multiforme (GBM) is the most lethal form of brain cancer. With the available treatments, survival does not exceed 12–14 mo from the time of diagnosis. We describe a novel strategy to selectively induce the death of glioblastoma cells and other cancer cells that overexpress the EGF receptor. Using a non-viral delivery vector that homes to the EGF receptor, we target synthetic anti-proliferative dsRNA (polyinosine-cytosine [poly IC]), a strong activator of apoptosis, selectively to cancer cells.

Methods and Findings

Poly IC was delivered by means of a non-viral vector: 25kDa polyethyleniminepolyethyleneglycol- EGF (PEI25-PEG-EGF). EGFR-targeted poly IC induced rapid apoptosis in the target cells in vitro and in vivo. Expression of several cytokines and ‘‘bystander killing’’ of untransfected tumor cells was detected in vitro and in vivo. Intra-tumoral delivery of the EGFRtargeted poly IC induced the complete regression of pre-established intracranial tumors in nude mice, with no obvious adverse toxic effects on normal brain tissue. A year after treatment completion the treated mice remain cancer-free and healthy. Similarly, non-viral delivery of poly IC completely eliminated pre-established breast cancer and adenocarcinoma xenografts derived from EGFR over-expressing cancer cell lines, suggesting that the strategy is applicable to other EGFR-over-expressing tumors.

Conclusion

The strategy described has yielded an effective treatment of EGFR over-expressing GBM in an animal model. If this strategy is translated successfully to the clinical setting, it may actually offer help to GBM patients. Moreover the elimination of two additional EGFR over-expressing cancers in vivo suggests that in principle this strategy can be applied to treat other tumors that over-express EGFR.